Patents Assigned to Merck
  • Patent number: 11010591
    Abstract: A protein crystallization trial is automatically analyzed by capturing images of the protein drops in the trial. A machine-learned model, such as a neural network, is applied to classify the images. The model generates a predicted classification from among a set of possible classifications which includes one or more crystal type classifications and one or more non-crystal type classifications. Users may be notified automatically of newly identified crystals (e.g., drops that are classified as a crystal type). The notification may include a link to a user interface that includes results of the trial.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: May 18, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Soheil Ghafurian, Ilknur Icke, Charles A. Lesburg, Belma Dogdas
  • Patent number: 11008338
    Abstract: In its many embodiments, the present invention provides certain C5-C6-oxacyclic fused iminothiazine dioxide compounds bearing an ether linker, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tautomers, wherein R1, R2, R3, RA, ring A, m, n, -L1-, ring B, RB, and p are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.
    Type: Grant
    Filed: March 17, 2020
    Date of Patent: May 18, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wen-Lian Wu, Jared N. Cumming, Brandon M. Taoka, Xing Dai
  • Publication number: 20210139451
    Abstract: The invention relates to compounds of the formula I in which groups and parameters that occur have the definitions given in Claim 1, to the preparation thereof, to the use thereof as components in liquid-crystalline media and to electrooptical display elements comprising the liquid-crystalline media of the invention.
    Type: Application
    Filed: June 11, 2018
    Publication date: May 13, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Lars LIETZAU, Achim GOETZ, Harald HIRSCHMANN, Martin ENGEL
  • Publication number: 20210139777
    Abstract: The present invention relates to a liquid-crystalline medium having a clearing point of 120° C. or more, comprising one or more compounds selected from the group of the compounds of the formulae IA, IB, IC, ID and II in which the groups and parameters occurring have the meanings indicated in Claim 1, in a total concentration of 65% or more, and to the use thereof for electro-optical purposes, in particular for liquid-crystal light valves for use in lighting devices for motor vehicles, to liquid-crystal light valves containing this medium, and to lighting devices based on liquid-crystal light valves of this type.
    Type: Application
    Filed: May 28, 2018
    Publication date: May 13, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Michael WITTEK, Dagmar KLASS
  • Publication number: 20210139781
    Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal (LC) media comprising them, and to the use of the polymerisable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment type.
    Type: Application
    Filed: March 6, 2018
    Publication date: May 13, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Dmitry USHAKOV, Kaja Christina DEING, Qiong TONG
  • Publication number: 20210139779
    Abstract: The invention relates to a liquid-crystalline medium, preferably having a nematic phase and dielectric anisotropy of 0.5 or more, which comprises one or more compounds of formula T in which and the other parameters have the meanings given in the text, to the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type, and to the compounds of formula T and their use for the improvement of the transmission and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds.
    Type: Application
    Filed: June 26, 2019
    Publication date: May 13, 2021
    Applicant: Merck Patent GmbH
    Inventors: Atsutaka MANABE, Constanze BROCKE, Sven BARAN, Sebastian HOFMEYER, Alexander HAHN
  • Patent number: 11001576
    Abstract: The present invention relates to novel compounds, particularly to compounds comprising a photoactive unit, said novel compounds being particularly suitable for compositions and ophthalmic devices as well as to compositions and ophthalmic devices comprising such compounds.
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: May 11, 2021
    Assignee: Merck Patent GmbH
    Inventors: Lars Dobelmann-Mara, Stefan Riedmueller, Martin Schraub
  • Patent number: 11005049
    Abstract: The present invention relates to metal complexes, to compositions and formulations comprising these complexes, and to devices comprising the complexes or compositions.
    Type: Grant
    Filed: July 25, 2014
    Date of Patent: May 11, 2021
    Assignee: Merck Patent GmbH
    Inventors: Heinrich Becker, Frank Voges
  • Patent number: 11005050
    Abstract: The present invention relates to metal complexes and to electronic devices, in particular organic electroluminescent devices, comprising these metal complexes.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: May 11, 2021
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Nils Koenen
  • Patent number: 11001640
    Abstract: The present invention provides a method for generating bispecific shark variable antibody domains (vNAR domains) and uses thereof. The present invention further provides fusion proteins comprising the inventive bispecific vNAR domains as well as polynucleotide libraries for use in the generation of the inventive bi-specific vNARs. Furthermore, the invention provides pharmaceutical compositions comprising the inventive bispecific vNARs or fusion proteins comprising bi-specific vNAR domains for use in the treatment of pathological conditions in an individual. The invention also provides kits of parts comprising the bispecific vNAR domains or fusion proteins.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: May 11, 2021
    Assignee: Merck Patent GmbH
    Inventors: Stefan Becker, Bjoern Hock, Stefan Zielonka, Harald Kolmar, Martin Empting
  • Patent number: 11005042
    Abstract: The present invention relates to formulations for the preparation of organic electronic devices which comprise at least one specific ketone solvent containing a non aromatic cycle and at least one organic functional material, preferably selected from organic conductors, organic semiconductors, organic fluorescent compounds, organic phosphorescent compounds, organic light-absorbent compounds, organic light-sensitive compounds, organic photosensitisation agents and other organic photoactive compounds, selected from organometallic complexes of transition metals, rare earths, lanthanides and actinides.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: May 11, 2021
    Assignee: Merck Patent GmbH
    Inventors: Gaëlle Béalle, Christoph Leonhard, Hsin-Rong Tseng, Irina Martynova, Aurélie Ludemann
  • Patent number: 11001561
    Abstract: The invention relates to pyrimidinone derivatives of the general Formula I, or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compound.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: May 11, 2021
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Roch Boivin, Theresa Johnson, Yanping Wang, Yufang Xiao, Xiaoling Chen, Nina Linde, Doreen Musch, Deepak Kumar
  • Publication number: 20210130684
    Abstract: Suggested is a semiconductor nano-sized light emitting material having a ligand.
    Type: Application
    Filed: October 10, 2018
    Publication date: May 6, 2021
    Applicant: Merck Patent GmbH
    Inventors: Sanaa KHALIL, Kobi ODED, Denis GLOZMAN, Ehud SHAVIV
  • Publication number: 20210130790
    Abstract: 3D cell cultures contain hepatic cells and are infected by a pathogen. Such cell cultures are prepared by, for example, inoculating a single-cell suspension containing hepatic cells expanded in a 2D culture in an agitation-based culture system. Next, the resulting cell culture is agitated at a given agitation rate. Then, the resulting 3D cell culture containing cell aggregates is incubated with a pathogen.
    Type: Application
    Filed: March 8, 2018
    Publication date: May 6, 2021
    Applicant: Merck Patent GmbH
    Inventors: Thomas Spangenberg, Beatrice Greco, Paula Maria Marques Leal Sanches Alves, Manuel José Teixeira Carrondo, Ana Catarina Maurício Brito Ataíde, Sofia Raquel Paulo Rebelo, Francisca Maria De Andrade Terras Arez, Daniel Filipe Mestre Simão, Rui Miguel Prudêncio Pignatelli, Diana Marisa Pinto Freire Fontinha, Marta Monteiro Maia Machado
  • Publication number: 20210130466
    Abstract: Therapeutic combinations that comprise at least one antagonist of the Programmed Death 1 receptor (PD-1) and at least one benzo[b]thiophene compound that activates the Stimulator of Interferon Genes (STING) pathway are disclosed herein. Also disclosed is the use of such therapeutic combinations for the treatment of cancers.
    Type: Application
    Filed: July 30, 2018
    Publication date: May 6, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Saso CEMERSKI, Jared N. CUMMING, Johnny E. KOPINJA, Samanthi A. PERERA, Benjamin Wesley TROTTER, Archie Ngai-Chiu TSE
  • Publication number: 20210130452
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of IL-17A, IL-17F and/or IL-17A/F including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: September 29, 2020
    Publication date: May 6, 2021
    Applicant: Merck Patent GmbH
    Inventors: Heidi ROMMELAERE, Joost Alexander KOLKMAN, Michael John Scott SAUNDERS, Ann UNION, Yolande CHVATCHKO, Amanda E.I. PROUDFOOT, Alain VICARI, Denis BRUNIQUEL, Laurent CHEVALET, Olivier LEGER
  • Publication number: 20210130693
    Abstract: The invention relates to a compound of formula I, wherein R11, R21, A11, A, Z, X11, X21, Y11, Y12, Sp11, Sp21, o and p have one of the meanings as given in claim 1. The invention further relates to method of production of a compound of formula I, to the use of said compounds in LC media and to LC media comprising one or more compounds of formula I. Further, the invention relates to a method of production of such LC media, to the use of such media in LC devices, and to LC device comprising a LC medium according to the present invention. The present invention further relates to a process for the fabrication such liquid crystal display and to the use of the liquid crystal mixtures according to the invention for the fabrication of such liquid crystal display.
    Type: Application
    Filed: April 18, 2019
    Publication date: May 6, 2021
    Applicant: Merck Patent GmbH
    Inventors: Lars LIETZAU, Simon SIEMIANOWSKI, Izumi SAITO
  • Patent number: 10995405
    Abstract: Transition metal precursors are disclosed herein along with methods of using these precursors to deposit metal thin films. Advantageous properties of these precursors and methods are also disclosed, as well as superior films that can be achieved with the precursors and methods.
    Type: Grant
    Filed: February 17, 2017
    Date of Patent: May 4, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Charles Dezelah, Jean-Sebastien Lehn, Guo Liu, Mark C. Potyen
  • Patent number: 10996225
    Abstract: Method, kit and composition for analyzing analytes for modifications using modification site specific antibodies to bind an analyte with his specific modification sites of interest to different dyes simultaneously with an antibody which is specific to the non-modificated analyte binding to another dye to determine the concentration of the analyte for quantification of the modified analyte in the identical sample.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: May 4, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Frank Jeahrling, Friedhelm Bladt, Jessica Witzgall
  • Patent number: 10995085
    Abstract: Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Also disclosed herein are uses of a compound disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of a composition in the potential treatment or prevention of an IDO-associated disease or disorder.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: May 4, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Yongxin Han, Abdelghani Achab, Yongqi Deng, Xavier Fradera, Craig Gibeau, Brett A. Hopkins, Derun Li, Kun Liu, Meredeth A. McGowan, Nunzio Sciammetta, David Sloman, Catherine White, Hongjun Zhang, Hua Zhou